A Phase II Study of BEZ235 in Patients with Everolimus-resistant, Advanced Pancreatic Neuroendocrine Tumours

BACKGROUND: This was a two-stage, phase II trial of the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor BEZ235 in patients with everolimus-resistant pancreatic neuroendocrine tumours (pNETs) (NCT01658436). PATIENTS AND METHODS: In stage 1, 11 patients received 400 mg BEZ23...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Anticancer Res
Autors principals: FAZIO, NICOLA, BUZZONI, ROBERTO, BAUDIN, ERIC, ANTONUZZO, LORENZO, HUBNER, RICHARD A., LAHNER, HARALD, DE HERDER, WOUTER W., RADERER, MARKUS, TEULÉ, ALEXANDRE, CAPDEVILA, JAUME, LIBUTTI, STEVEN K., KULKE, MATTHEW H., SHAH, MANISHA, DEY, DEBARSHI, TURRI, SABINE, AIMONE, PAOLA, MASSACESI, CRISTIAN, VERSLYPE, CHRIS
Format: Artigo
Idioma:Inglês
Publicat: 2016
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5076549/
https://ncbi.nlm.nih.gov/pubmed/26851029
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars